A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants

SARS-CoV-2 has caused the COVID-19 pandemic since early 2020. As of January 2022, the worldwide spreading of SARS-CoV-2 leads to approximately 0.35 billion of human infections and five millions of deaths. Current vaccination is one of the effective ways to control SARS-CoV-2 transmission and reduce...

Full description

Bibliographic Details
Main Authors: Joy-Yan Lam, Yau-Yee Ng, Chun-Kit Yuen, Wan-Man Wong, Kwok-Yung Yuen, Kin-Hang Kok
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Emerging Microbes and Infections
Subjects:
COVID-19
SARS-CoV-2
nasal protein vaccine booster
delta variant
omicron variant
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2022.2053365

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2022.2053365

Similar Items